272 related articles for article (PubMed ID: 33638680)
1. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.
Khayat-Khoei M; Conway S; Rubinson DA; Jarolim P; Houtchens MK
J Neurol; 2021 Oct; 268(10):3592-3594. PubMed ID: 33638680
[No Abstract] [Full Text] [Related]
2. Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations.
Mado H; Adamczyk-Sowa M
J Neurol; 2021 Nov; 268(11):3998-3999. PubMed ID: 33864125
[No Abstract] [Full Text] [Related]
3. Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.
Mado H; Kubicka-Bączyk K; Adamczyk-Sowa M
J Int Med Res; 2021 Sep; 49(9):3000605211044378. PubMed ID: 34528472
[TBL] [Abstract][Full Text] [Related]
4. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
5. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study.
Conte WL
Mult Scler Relat Disord; 2021 Jul; 52():103014. PubMed ID: 34000684
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer.
Mueller T
Clin Chim Acta; 2021 Jul; 518():9-16. PubMed ID: 33741357
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
9. Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination.
Kim N; Minn D; Park S; Roh EY; Yoon JH; Park H; Shin S
J Korean Med Sci; 2021 May; 36(21):e158. PubMed ID: 34060264
[TBL] [Abstract][Full Text] [Related]
10. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
Rastawicki W; Płaza K
Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
[TBL] [Abstract][Full Text] [Related]
11. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.
Ostadgavahi AT; Booth R; Sisson G; McMullen N; Warhuus M; Robertson P; Miller M; Allen WC; El Sherif M; Brownlie R; Falzarano D; Richardson CD
J Infect Dev Ctries; 2021 May; 15(5):653-656. PubMed ID: 34106888
[TBL] [Abstract][Full Text] [Related]
12. Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection, and change to single-dose vaccination.
Mungmunpuntipantip R; Wiwanitkit V
J Med Virol; 2021 Dec; 93(12):6474. PubMed ID: 34374991
[No Abstract] [Full Text] [Related]
13. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
van Kempen ZLE; Wieske L; Stalman EW; Kummer LYL; van Dam PJ; Volkers AG; Boekel L; Toorop AA; Strijbis EMM; Tas SW; Wolbink GJ; Löwenberg M; van Sandt C; Ten Brinke A; Verstegen NJM; Steenhuis M; Kuijpers TW; van Ham SM; Rispens T; Eftimov F; Killestein J;
Mult Scler Relat Disord; 2022 Jan; 57():103416. PubMed ID: 34847379
[TBL] [Abstract][Full Text] [Related]
14. [Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers].
Rojkovich B; Németh D; Török E; Szabó B; Pintér Á; Juhász I; Weidl M; Lányi É; Pável-Szecskó J; Lázár I; Perduk A; Reiter J; Nagy G; Nagy E; Géher P
Orv Hetil; 2021 Sep; 162(39):1551-1557. PubMed ID: 34570721
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
16. Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination.
Favresse J; Douxfils J
J Infect; 2022 Jan; 84(1):94-118. PubMed ID: 34233149
[No Abstract] [Full Text] [Related]
17. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
[TBL] [Abstract][Full Text] [Related]
18. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G
J Infect; 2021 Aug; 83(2):e4-e5. PubMed ID: 34214516
[No Abstract] [Full Text] [Related]
19. Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.
Conte WL
Mult Scler Relat Disord; 2020 Sep; 44():102315. PubMed ID: 32593144
[No Abstract] [Full Text] [Related]
20. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
